Cooper Companies reported strong financial results for fiscal 2024, with revenue increasing 8% to $3.9 billion and net income rising 33% to $392.3 million. CooperVision sales grew 8% to $2.6 billion driven by toric and multifocal lenses, while CooperSurgical revenue rose 10% to $1.3 billion supported by office/surgical and fertility segments.Operating income increased 32% to $705.7 million as gross margin held steady at 67%. The company maintained strong cash flow with $709.3 million generated from operations. During the year, Cooper completed strategic acquisitions including Cook Medical's obstetrics assets and obp Surgical to expand its surgical portfolio.Management identified a material weakness in IT controls at CooperSurgical's U.S. operations but has begun implementing remediation steps. The company ended the year with a solid balance sheet showing $2.6 billion in debt and remains well-positioned for continued growth through its diversified portfolio of vision correction and women's health products.

Cooper Companies reported strong financial results for fiscal 2024, with revenue increasing 8% to $3.9 billion and net income rising 33% to $392.3 million. CooperVision sales grew 8% to $2.6 billion driven by toric and multifocal lenses, while CooperSurgical revenue rose 10% to $1.3 billion supported by office/surgical and fertility segments.Operating income increased 32% to $705.7 million as gross margin held steady at 67%. The company maintained strong cash flow with $709.3 million generated from operations. During the year, Cooper completed strategic acquisitions including Cook Medical's obstetrics assets and obp Surgical to expand its surgical portfolio.Management identified a material weakness in IT controls at CooperSurgical's U.S. operations but has begun implementing remediation steps. The company ended the year with a solid balance sheet showing $2.6 billion in debt and remains well-positioned for continued growth through its diversified portfolio of vision correction and women's health products.